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Abstract 
In this study niosomes were generated from proniosomes (Span 60: 
Cholesterol 1:1) using beclomethasone dipropionate (BDP, 5 mole %) 
as a model drug. When niosomes were processed via probe sonication, 
photon correlation spectroscopy study showed that niosomes generated 
from proniosomes had larger size than conventional niosomes, being 
202 nm and 160 nm, respectively. Transmission electron microscopy 
(TEM) showed that these niosomes were highly aggregated. The zeta 
potential values of niosomes were negative regardless of the 
preparation method. However, a highly intense negative charge was 
detected for niosomes generated from proniosomes (-36 mV) compared 
to niosomes (-25 mV). The entrapment efficiency (EE) of BDP was 
higher in proniosomes-driven niosomes compared to conventional 
niosomes, being 35% and 27%, respectively.  
 Probe sonicated, niosomes manufactured using the proniosome 
technology were nebulised using either Pari LC Sprint (air-jet), Aeroneb 
Pro (actively vibrating-mesh) or Omron Micro Air NEU22 (passively 
vibrating-mesh) nebulisers. The Pari and Aeroneb Pro nebulisers 
generated higher aerosol and drug outputs compared with the Omron 
nebuliser. Whilst drug output was around 80% for the Pari and the 
Aeroneb Pro, it was around 70% for the Omron. Similarly, droplet size 
generated from the Omron was larger than that generated from the Pari 
and the Aeroneb Pro, being 4.86 µm, 3.06 µm and 3.32 µm 
respectively. Using laser diffraction for aerosol droplet size analysis, the 
Pari nebuliser generated aerosols with the highest fine particle fraction 
(FPF) (around 80%) followed by the Aeroneb Pro nebuliser 
(approximately 70%) and the Omron nebuliser (around 40%). The 
predicted alveolar deposition was negligible for the Omron and 
approximately 20% for the Aeroneb Pro and the Pari nebulisers. 
 Using niosomes generated from proniosomes, the high shear 
homogeniser (NanoDebee) has produced niosomes having a small size 
(Zaverage = 236.5 ±13 nm) which was comparable to probe sonicated 
niosomes (Zaverage =209.2 ±21.4 nm). The zeta potential was also 
similar, being, respectively -38 and -36 mV. Also similar EE values were 
found, being 36.4% ±2.8 and 29.65% ±4.04 for the probe sonicated 
vesicles and the Nano Debee-homogenised vesicles, respectively.  
 Probe sonicated niosomes generated from proniosomes were 
freeze-dried. Rehydration of freeze-dried niosomes caused a massive 
increase of the size (by 13 times) of niosomes, indicating instability of 
niosomes. 
 Overall, the study in thesis has demonstrated that niosomes 
generated from proniosomes were possible to be delivered via medical 
nebulisers with a high FPF using BDP as a model antiasthmatic drug. A 
large scale production method was introduced using high shear 
homogenisation. However, freeze-drying exerted a destabilising effect 
on niosomes, causing either massive aggregation or fusion of the 
vesicles. 
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1.1 Liposomes and niosomes 
In the recent years, continuous hard work has been done for 
development of drug carrier systems which are able to deliver active 
molecules specifically to the target organ, increase therapeutic efficacy 
and minimize adverse or side effects. Delivery systems may allow drug 
release to sustain for prolonged time in the targeted tissue, resulting in 
enhanced therapeutic efficacy, and minimised side effects due to the 
lower concentrations of the free drug in the blood (Lamprecht, 2009).  
Niosomes represent one of the promising drug delivery systems, with 
particular interest in delivery applications including nasal, pulmonary, 
transdermal and ophthalmic delivery. Liposomes and niosomes are able 
to entrap a wide range of therapeutic materials and release them at a 
slow rate to sustain the drug effect. Moreover, they can solubilise poorly 
soluble compounds, providing a tangible strategy to resolve formulation 
problems of many therapeutic molecules. Drug delivery to the pulmonary 
system comprises a strategy for treatment of local respiratory and 
systemic diseases. It has been previously demonstrated that pulmonary 
delivery of liposome-entrapped drugs can prolong drug residence in the 
respiratory tract which may reduce systemic side effects of the drug 
(Juliano and McCullough, 1980; Taylor et al., 1989). Unfortunately, 
liposomes in aqueous preparations are very unstable due to the 
presence of ester bond, and phospholipids may hydrolyse or oxidise 
during storage (Hunt and Tsang 1981; Kensil and Dennis 1981). 
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Therefore, research group of Dr Abdelbary Elhissi has investigated the 
potential of proliposome technologies as chemically stable alternatives to 
liposomes for pulmonary delivery via medical nebulisers (Elhissi and 
Taylor 2005; Elhissi et al., 2006). Other possible alternative involves 
formation of niosomes which are much more stable than liposomes 
(Baillie et al., 1985; Hu et al., 1999). Surprisingly, very little research has 
been conducted to investigate their potential in pulmonary delivery. 
 
Niosomes are also known as non-ionic surfactant vesicles, and 
have been regarded as an alternative to liposomes. Niosomes can be 
prepared by hydration of synthetic non-ionic surfactants either with or 
without cholesterol (Barry, 2001; Vila et al., 1979). Vesicle formation is 
not spontaneous since it needs input of some kind of energy, for instance 
via extrusion, heating or shaking of the surfactant aqueous dispersions 
(Lasic, 1988). Niosomes have many beneficial characteristics over 
liposomes such as stability on storage and ease of handling. Niosomes 
are prepared from non-ionic surfactants which are not toxic, 
biodegradable, biocompatible and non- immunogenic. In fact, the non-
ionic property of the surfactants used in preparation of niosomes is the 
reason behind the low toxicity of niosomal formulations (Yadav et al., 
2011). Incorporation of surfactants within niosomes may also enhance 
the efficacy of the drug, possibly by facilitating its uptake by the target 
cells.  
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The materials (non-ionic surfactants and cholesterol) which are 
used to prepare niosomes are much cheaper than those used to 
manufacture liposomes namely phospholipids. Also the stability of 
niosomes is higher than that of liposomes. These properties may 
contribute to making niosomes attractive drug carrier alternatives to 
liposomes (Vyas et al., 2005; Nasseri et al., 2005).    
 
Cholesterol is included in most niosome formulations in order to 
increase rigidity of the noisome membranes and subsequently improve 
stability of the vesicles and to reduce permeability of the encapsulated 
material (Nasseri et al., 2005; Guinedi et al., 2005). The in vivo behaviour 
of niosomes might be similar to that of liposomes, and can extend the 
circulation of entrapped drug in the blood, causing an alteration in organ 
distribution and metabolic stability of the encapsulated material 
(Ruckmani et al., 2000). 
 
1.2 Niosomal preparation methods 
There are several methods that are used to prepare niosomes. These 
methods are highly similar to those used to prepare liposomes. With 
regard to preparation, the main difference between liposomes and 
niosomes is that niosomes require higher energy input to be formed. The 
preparation methods influence the niosome characteristics, and hence 
the right method should be employed to manufacture niosomes of the 
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right characteristics. The most frequently used methods to prepare 
niosomes have been reported by Uchegbu and Vyas, (1998) and Yadav 
et al., (2011). These methods are listed below. 
 
1. Thin-film hydration:  
Surfactant and cholesterol are dissolved in organic solvent (e.g. 
chloroform) within a round bottomed flask followed by solvent 
evaporation using a rotary evaporator to leave a thin layer of the lipid 
phase on the inner wall of the flask. The thin film is then hydrated by 
aqueous phase at 0-60ºC with gentle shaking. This method is used to 
generate multilamellar niosomes (Baillie et al., 1986; Guinedi et al., 
2005). 
 
2. Ether injection:  
This method depends on dissolving the surfactants in diethyl ether and 
injecting this solution into previously heated water (60ºC). Single layered 
vesicles are formed upon evaporation of ether. The disadvantage of this 
method is the possible residual ether left in the niosome preparation 
(Baillie et al., 1985; Carter et al., 1988). 
 
3. Reverse phase evaporation:  
This method is based on the formation of water in oil (w/o) emulsion, so 
that an aqueous solution is dispersed in an organic mixture of surfactant 
and cholesterol. Before emulsification, the drug is dissolved either in the 
aqueous or organic phase, depending on its solubility. The emulsion is 
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dried by evaporating the organic solvent using a rotary evaporator to 
disperse the niosomes in the aqueous phase. In other cases, the 
emulsion is dried to a semi-solid gel which needs to be hydrated to yield 
niosomes, which is employed to generate large unilamellar niosomes 
(Guinedi et al.2005; Naresh et al., 1994). 
 
4. Proniosome technology:  
This method comprises a stable free-flowing dry formulation of surfactant 
and cholesterol. Proniosomes are prepared by dissolving the 
surfactant/cholesterol in an organic solvent followed by spraying this 
mixture to coat a water-soluble carrier such as sucrose, sorbitol or other 
carbohydrates. After evaporation of the organic solvent a thin coat is left 
on the carbohydrate carrier particles; this formulation is referred to as 
proniosomes. The addition of an aqueous phase with shaking generates 
niosomes (Blazek-Walsh and Rhodes, 2001).  
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1.3 Materials used for preparation of niosomes 
 
1.3.1 Cholesterol  
 
Cholesterol (C27H45OH) is a material present in cell membranes of most 
animals. The chemical structure of cholesterol is shown in Fig. 1.1. 
Cholesterol influences membrane properties such as fluidity, enzymatic 
activity, ion permeability and elasticity as well as cell size and shape 
(Nasseri, 2005). Furthermore, cholesterol increases the stability and 
rigidity of niosome vesicles and reduces their aggregation. Cholesterol 
inclusion in niosomes as 1:1 mole/mole with non-ionic surfactants is the 
maximum concentration which can be beneficial for incorporation into 
niosomes in terms of vesicle stability (Nasseri, 2005; Leekumjorn, 2004; 
Uchegbu and Florence, 1995). 
 
As mentioned in a previous study (Uchegbu and Florence, 1995), 
polyhedral noisome vesicles which are prepared with low amount of 
either cholesterol or with non-ionic surfactants without cholesterol 
seemed to lose their viscoelasticity after facing high shearing, for 
instance during extrusion. This may cause the niosomes to deform 
permanently into tubular structures. However, the spherical niosomes 
that include cholesterol may regain their original shape after releasing the 
pressure, suggesting that cholesterol may increase vesicle elasticity 
(Nasseri, 2005; Nasseri and Florence 2003)  
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Fig 1.1: Structure of the cholesterol (adapted from: Sigma- Aldrich) 
 
1.3.2 Non-ionic surfactants  
 
Niosome formulations are made from non-ionic surfactants (amphiphilic 
structure) and aqueous solvents. Cholesterol is included in the noisome 
formulations in order to enhance vesicle stability and moreover, to reduce 
permeability of the encapsulated material. The aggregation of the 
vesicles can be decreased using molecules which stabilise the system 
and prevent or minimise the formation of aggregates by repulsive steric 
or electrostatic effects such as sorbitan monostearate (span 60). 
Electrostatic stabilisation could also be a charge inducer like 
dicetylphosphate. Different non-ionic surfactants are used in the literature 
to prepare niosomes. The surfactants used in niosome formulations must 
have both polar (hydrophilic) head group and non-polar (hydrophobic) 
tail. The non-polar tail can have one or two alkyl or perfluoroalkyl groups 
or a single steroidal group. The length of the alkyl group is usually 12-18 
carbon atoms (Uchegbu and Vyas, 1998). The spans (sorbitan 
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monoesters) are surfactant molecules which can be used to prepare 
niosomes. Spans are a group of non-ionic surfactants that have shown 
very good commercial utilization (Namedo and Jain, 1999). 
 
As described by Nasseri and Florence (2003), the nature of surfactant is 
also very important. For instance, ether-linked surfactants with dialkyl 
ether chain tail are less toxic than those having a single alkyl chain. In 
addition, ether-linked surfactants are chemically more stable than ester-
linked surfactants. In addition, ester-linked surfactants are less toxic 
because esterases biodegrade to triglycerides and fatty acids. As 
mentioned previously, surfactants containing alkyl chain with length of 
12-18 carbons are useful for preparation of niosomes (Nasseri and 
Florence, 2003).  
 
1.4 Proniosome technology as an approach to generating 
niosomes 
Niosomes of different characteristics can be prepared using different 
methods such as the conventional (thin film) method and the proniosome 
technology (Hu and Rhodes 1999). Proniosomes are surfactant-coated 
carbohydrate carrier particles (Fig. 1.2) that generate niosomes upon 
addition of aqueous phase (Hu and Rhodes 1999). The generated 
niosomes have been reported to be similar to conventional niosomes and 
more consistent in size. The advantage of using proniosomes is the 
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minimized physical instability such as aggregation and sedimentation of 
the vesicles and reduced drug leakage, and most importantly stability 
upon storage. Proniosomes are also easier to ship, and hence 
proniosome technology may be considered a stable and economical 
alternative to conventional niosomes (Yadav et al., 2011). 
 
 
 
Fig 1.2: Proniosome derived niosomes. Proniosomes are 
carbohydrate (e.g. sucrose) carrier particles coated with surfactant 
and cholesterol. Niosomes are generated from proniosomes by 
addition of water and shaking. This can be followed by vesicle size 
reduction via sonication 
 
1.5 Characterisation of the non-ionic surfactant vesicles 
To be able to evaluate niosomes, a range of studies are required and 
commonly performed. Size and polydispersity of niosomes are commonly 
analysed using laser diffraction or photon correlation spectroscopy, 
depending on the method of preparation while zeta potential (surface 
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charge) of niosomes is analysed using laser Doppler velocimetry 
(Marianecci et al., 2010). The lamellarity and morphology of niosomes 
are studied using microscopic techniques such as Transmission Electron 
Microscopy (TEM). Since niosomes may provide real advantages by 
entrapping a wide range of therapeutic molecules, it is important to 
determine the entrapment efficiency of such molecules. The entrapment 
efficiency (EE) of a given drug can be calculated according to the 
following equation: 
EE (%) = (amount of drug entrapped / total amount of the drug) × 100%
  
1.6 Respiratory tract 
The respiratory system is divided into upper respiratory tract and lower 
respiratory tract. The upper respiratory tract includes the nose, 
nasopharynx, mouth, larynx, trachea and bronchi while the lower 
respiratory tract includes bronchioles and alveoli. The lungs are 
responsible for respiration and are positioned on the either side of the 
mediastinum bordered by the right and left pleural cavities.  
The trachea is the top end of the lungs and is divided into the left and 
right bronchi. This is divided again to lead into narrower airways. The 
main bronchi are the place where the air enters and leaves continuously. 
This branching system will eventually end at the alveolar region (Fig. 
1.3). Oxygen entering the blood through the blood vessels in the vicinity 
of the alveoli is carried to the rest of the body. The pulmonary arteries 
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transport blood with low oxygen levels from the right ventricle to be 
oxygenated. Blood containing oxygen circulates back to the left atrium 
through the pulmonary veins and then to the left ventricle to be pumped 
to the rest of the body (Drake et al., 2005). 
 
 
Fig 1.3:  A detailed diagram of the respiratory system. The lungs are 
divided into upper respiratory tract and lower respiratory tract. The 
upper respiratory tract includes the nose, nasopharynx, mouth, 
larynx, trachea and bronchi. The lower respiratory tract consists of 
the bronchioles and alveoli. (Accredit by national heart lung and 
blood institute and adapted from: 
http://www.nhlbi.nih.gov/health/health-
topics/topics/hlw/system.html) 
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1.7 Pulmonary drug delivery 
Drug delivery to the respiratory system has been shown to be an 
important route for drug administration. The advantage of this route over 
alternative delivery routes is the suitability of this route for delivering low 
doses of the drug directly to the lung for treatment of local diseases 
within the respiratory tract (e.g. asthma) which may lead to elicit a rapid 
therapeutic response and potential avoidance of systemic side effects 
(Dolovich and Dhand, 2011). Therefore, inhalation of medical aerosols is 
a smart approach for treatment of local diseases in the lung such as 
chronic obstructive pulmonary diseases (COPD), pulmonary infectious 
diseases, respiratory distress syndrome (RDS), cystic fibrosis and 
asthma.  
 
Pulmonary drug delivery may also be beneficial for delivering 
drugs that have systemic therapeutic effects. The large pulmonary 
surface area and thinness of the alveolar walls make systemic absorption 
highly convenient (Dolovich and Dhand, 2011; Marianecci et al., 2010).  
 
         It has been shown previously that aerosolisation of drug-loaded 
vesicles (e.g. liposomes) can reach the lower respiratory tract and 
extend the drug release. Also, this strategy may limit the distribution of 
the drug to the other tissues that are distant from the lung, leading to 
minimised systemic side effects. Liposome vesicles have stability 
problems (e.g. phospholipid oxidation or hydrolysis), and hence, finding 
14 
 
alternatives to liposomes is desirable. Niosomes are similar to 
liposomes in their function and are more chemically stable and cheaper 
to manufacture (Hao et al, 2002). This suggests that non-ionic 
surfactant vesicles (niosomes) should be studied for pulmonary drug 
delivery. 
 
           Many drugs are used to treat local diseases in the lung. 
However, antiasthma drugs (e.g. beclomethasone dipropionate) are still 
the most popular because of the large number of asthmatic patients. 
Glucocorticoids (e.g. beclomethasone dipropionate) are generally used 
via inhalation and systemic treatments for the inflammatory lung 
diseases (e.g. asthma).  
 
1.8 Asthma 
Asthma is defined as a reversible partial obstruction to airflow in the 
intrathoracic airways (Axford and O’Callaghan, 2004). In normal 
situations, the muscle around the bronchi is smooth, which causes a 
normal response to external or internal stimuli. People who have asthma 
have an abnormal increased reaction to stimuli. This phenomenon is 
termed as “bronchial hyper-reactivity” which may happen because of 
inflammatory-mediated mechanisms. Frequently stimuli can cause 
ongoing bronchial inflammation in susceptible individuals, and this may 
prolong bronchial hyper-reactivity.  
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There are two different types of stimuli to bronchus which are 
specific and non-specific. Specific stimuli include inhaled allergens such 
as house dust, mite and pollen. There are also occupational allergens 
like drugs (e.g. aspirin). Specific stimuli are more responsible to cause 
ongoing bronchial inflammation than non-specific bronchial stimuli and 
this can result in lasting bronchial hyper-reactivity. The non-specific 
bronchial stimuli include viral infections, cold air, exercise, emotional 
stress and inhaled pollutants such as perfumes. The difference between 
normal and obstructive respiratory airways is shown in Fig. 1.4. 
 
Asthma may also be classified into allergic and non-allergic. 
People who have allergic asthma have higher levels of IgE (allergy 
antibody) circulating in their blood. In general these asthmatic individuals 
have positive skin prick tests to common allergens.  The symptoms 
usually occur in childhood and there is a tendency for the symptoms to 
improve during later ages (e.g. adolescence). When these asthmatic 
patients avoid the allergens, the symptoms can improve and their quality 
of life may enhance. Non-allergic asthmatics may develop in middle age 
people, in general those people who are not atopic and the symptoms 
tend to be progressive and remitting (BNF, 2009; Drake et al., 2005). 
 
Asthma is a disease that negatively affects the quality of life of 
asthmatic patients. However, importantly, severe asthma is life-
threatening and can happen suddenly (acute severe asthma) or as the 
end stage of slowly deteriorating asthma (chronic worsening asthma). 
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Acute severe asthma can be precipitated by either emotional stress or a 
viral infection, but chronic worsening asthma usually develops over 
weeks with a slow increase in symptoms and progressive failure to 
respond to inhaled ß2- agonists. 
 
Fig 1.4:  A diagram showing the location of the lungs and 
airways in the human body. B diagram showing normal airways 
versus airways during asthma symptoms (Accredit by national 
heart lung and blood institute and adapted from: 
http://www.nhlbi.nih.gov/health/health-topics/topics/asthma/) 
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Stages of asthma management 
Asthma management should be stepwise in children and adults as 
instructed by the guidelines of the British National Formulary (BNF) 
(BNF, 2009): 
 
1. Occasional relief bronchodilators  
Inhaled short acting ß2-agonist (e.g. salbutamol) when required. Regular 
inhaled prophylactic therapy - inhaled short acting ß2-agonist as 
required with regular standard dose of inhaled corticosteroid such as 
beclomethasone dipropionate (BDP). 
 
           2.    Inhaled corticosteroids and long acting ß2-agonist - 
inhaled short acting ß2- agonist when required plus regular inhalation of 
corticosteroid and regular inhalation of long acting ß2-agonist (e.g. 
salmeterol or formeterol) if asthma is still uncontrolled. The dose of 
inhaled corticosteroid should be increased to upper end of standard dose 
and either stop long acting ß2-agonist if no benefit or continued if of some 
benefit. If the asthma is still not controlled and long acting ß2-agonist 
stopped, the leukotriene receptor antagonist should be added to the 
therapy plan. Modified release oral theophylline and modified release oral 
ß2-agonist may also be used. 
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         3. High dose inhaled corticosteroid plus regular 
bronchodilators - inhaled short-acting ß2-agonist with regular high 
dose corticosteroid plus one or more long-acting bronchodilators may 
be given. In adults, 6 week trial of one or more of these following drugs 
may be given they include: leukotriene receptor antagonist, modified 
release oral thoephylline or modified release ß2-agonist. 
 
Regular corticosteroid tablets – It is recommended that the 
patients inhale short acting ß2-agonist with regular high dose inhaled 
corticosteroids and one or more long acting bronchodilators plus regular 
oral corticosteroids as a single daily dose (e.g. prednisolone tablets) are 
recommended. In addition to oral prednisolone, the patient should 
continue to use a regular high dose corticosteroid.  
 
1.9 Mechanisms of particle deposition 
The ability of particles to reach the lower pulmonary airways is 
dependent on their size, since the anatomy and physiology of the 
respiratory system can produce defence against the deposition of 
airborne particles in the lower respiratory regions.  
 
This must be recommended when taking particle size as the prime 
determinant of particle deposition in the airways, there are three 
important mechanisms: inertial impaction, Brownian diffusion and 
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sedimentation. There are also two other mechanisms which are less 
important namely interception which is dependent on particle shape and 
electrostatic precipitation which is dependent on particle charge. The 
dominant mechanism of particle deposition in the respiratory tract is 
inertial impaction deposition for particles larger than 5 μm. However, 
particles larger than 12 μm will be highly likely to deposit in the 
extrathoracic region, and hence particles > 12 μm are not likely to deposit 
in the respirable region of the lungs (bronchioles and alveolar region) 
(Heyder, 1982).  
 
Particles with either high velocity or density are expected to impact 
in the upper regions of the respiratory tract depending also on particle 
size. For example light (low density) particles are more expected to move 
with air streamlines and travel deeper into the lung for effective 
deposition in the lower airways (Maa et al., 1999). As mentioned before, 
Brownian diffusion is also a deposition mechanism. This deposition 
mechanism is more suitable for particles <1 μm (Tsuda et al., 1994). 
Random bombardment of the gas molecules with the particles may 
cause particle deposition on the respiratory airway walls. This happens in 
the alveolar region where airflow velocity is negligible. Sedimentation 
could also be a deposition mechanism.  The confrontation to the airflow 
which is increased in the lower airways especially in the alveolar region 
results in reducing the velocity of the inhaled gas. As a result of 
prolonged time of residence in the airways, large mass particles might 
deposit by sedimentation. The sedimentation mechanism might deposit 
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particle with the size between 1-5 µm in the effective region of the 
airways (Martonen and Yang, 1996). 
 
In principle, particles size smaller than 5- 6 µm is required for 
possible deposition in the lower airways to have a therapeutic effect. 
Particles with a size < 2 µm are preferred for alveolar deposition, which is 
a highly necessary target in the anti-inflammatory therapy of various 
diseases. Even though the percentage fraction of particles smaller than 
5-6 µm (i.e. the “fine particle fraction” (FPF)), deposition of particles in the 
lower airways is not guaranteed as it might be dependent on other 
pathological and physiological factors as well as other physical factors of 
the particles (Newman et al., 1982; O’Callaghan and Barry, 1997; 
Terzano et al., 2007). 
 
1.10 Inhalation devices 
There are three different types of inhalation devices. These are 
pressurised metered dose inhalers (pMDIs), dry power inhalers (DPIs) 
and nebulisers. The pMDI contains a pressurised propellant gas with the 
medicinal ingredient within a metallic canister. Upon actuation of the 
canister by pressing on the top of it, a metered dose of the propellant is 
released carrying a specific amount of the drug. The propellant 
evaporates because of its very high vapour pressure, leaving very small 
particles of the drug for inhalation. The propellant gas in the inhaler is 
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chlorofluorocarbon (CFC) and recent environmental regulations have 
restricted the use of such propellants due to their damaging effects on 
the ozone layer. Hydrofluoroalkanes are the most recently used 
propellants, but their inability to dissolve some amphipathic materials 
may limit their use for solubilising phospholipids and surfactants (Elhissi 
and Ahmed, 2011). The drug is stored within the spacer until the valve of 
the spacer opens by the intake of breath and then closes on exhalation.  
 
Dry powder inhalers (DPIs) are alternatives to pMDIs. These are 
powdered formulations of micronised drug adsorbed onto lactose carrier 
particles. The formulation is loaded into specially designed devices, and 
upon inhalation the micronised drug is detached from the carrier particles 
and inhaled whilst the carrier deposits in the upper regions of the 
pulmonary airways (Elhissi and Ahmed, 2011).  
 
The third type of inhalation devices are nebulisers. These devices 
generate aerosols of the drug dissolved or dispersed in an isotonic 
aqueous phase. The aerosol cloud is effectively inhaled via a face mask 
or a mouthpiece. This device is commonly used in hospitals for severe 
asthma attacks or when large drug doses are required at homes, and the 
drug is delivered by normal breathing (Elhissi and Ahmed, 2011).  
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1.11 Nebulisers 
Nebulisers have been widely investigated for their efficiency in delivery of 
regular solutions, suspensions and novel drug delivery systems to the 
respiratory tract (Elhissi and Ahmed, 2011). Nebulisers are highly 
convenient to use and can aerosolise large volumes of therapeutic 
aerosols to deep lung. Unlike DPIs and MDIs, nebulisers can aerosolise 
solutions or dispersions which do not require complicated procedures to 
prepare (O’Callaghan and Barry, 1997).  
 
 In a retrospective-cohort study, Marcus et al (2006) indicated that 
old patients who are using nebulisers to inhale corticosteroids 
persistently have shown reduced visits to the emergency department and 
less use of the systemic corticosteroids compared to before nebulisation. 
These positive outcomes did not increase health care costs, suggesting 
that nebulisers are preferred as the inhalation device by many patients.  
 
 Delivery of aerosols using nebulisers is dependent on the 
nebuliser’s operating principle, design and aerosol characteristics. The 
most important critical issue is the size of aerosol droplets and drug 
output of the nebuliser (Terzano et al., 2007). The required size of the 
particles should be less than 5-6 μm to be able to deliver the drug to the 
lower respiratory tract. However, to target some other specific deeper 
regions in the lung (e.g. the alveoli) smaller size of droplets is required 
(Bridges and Taylor, 2000a).  
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In the market, there are three different types of nebulisers: air-jet 
nebulisers, ultrasonic nebulisers and vibrating-mesh nebulisers. 
Ultrasonic nebulisers are being increasingly replaced with the new 
generation of vibrating-mesh nebulisers. Therefore, ultrasonic nebulisers 
will not be discussed in this review.  
 
 
Air-jet nebulisers 
Air-jet nebulisers are also named jet or pneumatic nebulisers. 
Sometimes, they are called compressor nebulisers since they are 
attached to air compressors (Elhissi and Ahmed, 2011). The first medical 
inhalation device known for production of aerosols was the jet nebuliser. 
Air-jet nebulisers have been extensively studied for the treatment of 
asthma in delivery of the anti-asthma formulations to the respiratory tract 
(Meurs, 1997; O’Callaghan and Barry, 1997). Modern jet nebulisers 
convert liquid formulations into aerosol droplets by using a high velocity 
gas passing through a narrow nozzle. An area of negative pressure is 
formed on top of the medical fluid. This creates filaments of the liquid that 
collapse into droplets because of liquid’s surface tension (McCallion et 
al., 1996a; O’Callaghan and Barry, 1997; Elhissi et al., 2006).  
 
A small amount of aerosols are suitable to be released for 
inhalation, while the largest amount of aerosol droplets generated from 
the liquid are too large (15-500 µm). Therefore, this fraction will be 
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deflected and recycled by the baffles within the nebuliser for further 
fragmentation into inhalable aerosols (McCallion et al., 1996a; 
O’Callaghan and Barry, 1997and Vecellio, 2006). Fig. 1.5 shows a 
schematic presentation of an air-jet nebuliser. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.5: A schematic presentation of an air-jet nebuliser (Source: 
Vecellio, 2006) 
 
The different design of the air-jet nebulisers results in different 
aerosol characteristics (output, size of the droplets, etc.) (Clay et al., 
1983; Hurley and Smye, 1994; Niven and Brain, 1994; Hess et al., 1996; 
O’Callaghan and Barry, 1997). 
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Air-jet nebulisers may be sub-classified into different types which 
are defined by the output during the inhalation. Firstly, Conventional jet 
nebulisers can generate a fixed flow rate of the gas containing aerosols. 
This nebuliser has a constant aerosol output during inhalation and 
exhalation times by the patient which results in wasting of a large 
proportion of the generated aerosols (Vecellio, 2006). 
 
Secondly, Open vent nebulisers. This type of nebuliser works 
constantly like the conventional jet nebulisers, but incorporates an extra 
air vent which deals with the negative pressure in the nebuliser. The fluid 
from the feeding tubes and air will be sucked, resulting in an improved 
airflow through the nebuliser which drives smaller aerosol droplets for 
inhalation over a certain length of time. Consequently, the time for 
nebulisation to be completed is shorter (O’Callaghan and Barry, 1997).  
 
Thirdly, Breath-enhanced (assisted) nebulisers. A common 
example of this type is the Pari LC nebuliser (Fig. 1.6). This nebuliser is 
designed to generate high aerosol output during inhalation and lower 
aerosol output during exhalation. This is attributed to the presence of a 
valve on the top of the device, which opens during inhalation to permit 
extra air to be sucked through the nebuliser. The valve closes during 
exhalation, resulting in decreased air flow through the nebuliser. 
However, there is another vent which is present at the top of the 
mouthpiece and opens during exhalation. This type of nebuliser 
26 
 
increases the amount of the drug inspired (O’Callaghan and Barry, 1997; 
Vecellio, 2006).  
 
Finally, Breath-actuated or Dosimetric nebulisers have been 
commercialised. This type of nebuliser generates aerosols only during 
inhalation, and hence aerosol wastage is minimised during exhalation 
(Vecellio, 2006).  
 
 
 
Fig 1.6: A breath-enhanced open vent air-jet nebuliser. The 
schematic diagram shows how the vent system operates during 
inhalation (left) and exhalation (right) (Source: O’Callaghan and 
Barry, 1997) 
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Vibrating-mesh nebulisers 
This group of nebulisers is based on the vibrating-mesh technology 
(Dhand, 2002). To generate aerosols all the nebulisers of this type 
employ vibrating mesh or plates with multiple apertures. These 
nebulisers are hand held, easy to carry and can operate using batteries 
(Dhand, 2002; Vecellio, 2006). According to the mechanism of nebuliser 
operation, these devices are divided into passively vibrating and actively 
vibrating-mesh nebulisers (Elhissi and Ahmed, 2011).   
 
Passively vibrating-mesh nebulisers  
 
After applying an electrical current, the incorporated piezoelectric crystal 
vibrates at high frequency. The crystal vibrations are transmitted to a 
transducer horn which is in contact with the medical fluid. This produces 
“passive” vibrations (upward and downward) movements of the mesh, 
which extrudes the fluid through the mesh apertures (around 6,000 
apertures) to generate aerosol. The flow rate and particle size of the 
aerosols are determined by the diameter of the mesh aperture which is 
around 3 µm for the Omron NE-U22 (Dhand, 2002; Vecellio, 2006; 
Ghazanfari et al., 2007; Elhissi and Ahmed, 2011) (Fig. 1.7). 
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Fig 1.7: The design of the Omron MicroAir NE-U22 nebuliser (left). 
The vibrations transmitted via the horn transducer from the 
piezoelectric crystal causes “passive” vibrations of the perforated 
plate, resulting in aerosol generation (right) (Source: Ghazanfari et 
al, 2007). 
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Actively vibrating-mesh nebulisers  
 
This type of nebulisers generates aerosols by using a “micropump” 
system, which employs an aerosol generator that includes around 1,000 
electroformed holes surrounded by a vibrational element. This causes an 
upward and downward movements of the mesh when an electrical 
current is applied to generate the aerosol (Fink et al., 2001a; 
Gopalakrishnan and Uster, 2001; Dhand, 2002; Elhissi and Ahmed, 
2011).  An example of that is the Aeroneb Pro nebuliser (Fig. 1.8). 
 
 
Fig 1.8: The design of the Aeroneb Pro vibrating-mesh nebuliser 
(left). A perforated plate is surrounded by a vibrational element that 
is attached to an electrical current (middle). This causes the mesh 
to vibrate and extrudes the medical fluid through the apertures to 
generate aerosols (right) Source: Ghazanfari et al, 2007). 
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1.12 Asthma therapy using glucocorticoids (Beclomthasone 
dipropionate)  
The delivery of glucocorticoids to the respiratory tract has been 
extensively studied for local treatment of inflammatory lung diseases 
(e.g. asthma) (Marianecci et al., 2010). Currently, inhaled glucocorticoids 
are the first line therapy for prophylactic treatment of asthma (Leflein et 
al., 1995). 
 
Glucocorticoids act by reducing the synthesis of arachidonic acid, 
blocking the expression of COX-2 and enhancing the sensitivity of β-
adrenoceptors. All these actions happen when glucorticoids bind to 
specific intracellular receptors (Trevor and Katzung, 2008). 
 
Beclomethasone dipropionate (BDP) is a hydrophobic antiasthma 
drug (Fig. 1.9). Because of beclomethasone dipropionate hydrophobicity, 
its formulations are made as suspensions which might be used in 
nebuliser therapy (Marianecci et al., 2010).  
 
BDP has an inactive prodrug structure with low receptor binding 
affinity. BDP requires to be changed to its active form 17-
beclomethasone monopropionate with high binding affinity to the 
receptors. The activation of the prodrug (BDP) is caused by esterases in 
the respiratory tract. Furthermore, the active metabolite 17-
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beclomethasone monopropionate is metabolised to beclomethasone 
(Winkler et al., 2004).  
 
The administration of glucocordicoids directly to the respiratory 
tract may cause localised side-effects such as candidiasis, since a 
fraction of the drug can be deposited in the mouth and oropharynx. The 
cause of such side-effects can be reduced using the prodrug form by 
inhalation, since the fraction deposited in the mouth and oropharynx will 
be consumed before the activation happens (Winkler et al., 2004). 
 
 
 
Fig 1.9: Chemical structure of Beclomethasone dipropionate 
(Adapted from Sigma- Aldrich) 
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1.13 Working Hypothesis 
Is it possible to develop BDP proniosome formulations that would 
generate niosomes for drug delivery via medical nebulisers to the 
respiratory tract? 
 
1.14 Aims of the study 
1. To formulate niosomes which are potentially applicable in  
            pulmonary delivery of antiasthma steroids using medical  
            nebulisers.  
 
2. To investigate a large scale manufacturing approach to hydrating  
              proniosomes and generating noisomes by using high pressure  
            homogenisation.  
 
3. To study the effect of freeze-drying on the stability of niosomes. 
 
4. To generate niosomal aerosols using medical nebulisers and  
            analyse the aerosol properties. 
 
5. To quantify the entrapment of the steroid before and after  
            nebulisation. 
 
6. To analyse the data and write up the MSc thesis by research. 
  
 
 
 
Chapter 2 
 
 
 
 
Materials and Methods 
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2.1 Materials 
All chemicals and consumables used in this study for preparation and 
analysis of niosomes and proniosomes were purchased from Sigma 
Aldrich, UK or Fisher Scientific, UK. All chemicals and consumables 
(Table 2.1) are analytical or pharmaceutical grade.  
 
Table 2.1: Materials used in the preparation and analysis of 
proniosomes and niosomes 
 
 
 
 
Material 
 
Supplier 
Sorbitan monostearate (Span 60) Sigma Aldrich, UK 
Cholesterol (99%) Sigma Aldrich, UK 
Sucrose Fisher Scientific, UK 
Methanol Fisher Scientific, UK 
Chloroform Fisher Scientific, UK 
Phosphate buffered saline (PBS) tablets Sigma Aldrich, UK 
Beclomethasone dipropionate (BDP, 
≥99%) 
Sigma Aldrich, UK 
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2.2. Methods                                                
2.2.1. Preparation of niosomes using thin film hydration method  
  
Niosomes were prepared from two different components, namely the 
non-ionic surfactant Span 60 and cholesterol (1:1) to constitute a quantity 
of 150 µmols. This was achieved by using Span 60 (32.2 mg) and 
cholesterol (29 mg). The mixture was placed into a 100 ml round bottom 
flask and dissolved in chloroform (3 ml). The organic solvent (chloroform) 
was removed under vacuum using a rotary evaporator (Buchi Rotavapor 
R-114, Buchi, Swizerland) at a rotation speed of 150 rpm with the flask 
being partially immersed in a water bath previously adjusted to 60oC. 
After 1 hr, the rotary evaporator was switched off, the negative pressure 
released and the flask was detached. A thin film of dry 
surfactant/cholesterol mixture was seen on the inner surfaces of the 
flask. The dry film was hydrated with an isotonic solution of PBS (10 ml; 
35-40°C) followed by hand-shaking for 10 minutes. The niosomal 
suspension was left overnight to ensure complete hydration of surfactant 
molecules and proper formation of niosomes. The same formulation was 
made using BDP (5 mole %) within the lipid phase (i.e. surfactant and 
cholesterol). The hydration procedure took place as for drug-free thin 
film. After preparation of noisome formulations (including or excluding 
BDP), samples were taken for size and zeta potential analysis of the 
vesicles using the Zeta sizer instrument (Malvern Instruments, UK). 
Other samples were taken to study the morphology of niosomes using 
transmission electron microscopy (TEM). 
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2.2.2. Bath sonication of niosomes 
 
Niosomes prepared by thin film hydration (section 2.2.1) were sonicated 
for 15 min using a bath sonicator to reduce the size of the vesicles. This 
was followed by size, zeta potential and microscopic morphology studies.  
 
2.2.3. Probe sonication of niosomes 
 
Niosomes prepared by thin film hydration (section 2.2.1) followed by bath 
sonication (2.2.1) were probe sonicated for 3 min with intermittent cooling 
of the preparation every 30 sec for 2 min in order to avoid overheating of 
the formulation. Characterisation studies were conducted for niosomes 
employing either thin film or bath sonication. 
 
2.2.4. Manufacture of niosomes using the proniosome method 
 
As for conventional niosomes (i.e. vesicles made by thin film method), 
the lipid phase (surfactant/cholesterol mixture (1:1) with or without 5 
mole% BDP) was dissolved in chloroform and sprayed onto sucrose 
carrier particles (300-500 µm) within a round bottomed flask using the 
rotary evaporator with a feed-line tube (Fig. 2.1). Spraying the 
chloroformic solution was performed in portions with each comprising 1 
ml in order to coat the carbohydrate particles uniformly and permit 
complete evaporation of the chloroform. This was allowed by rotary 
evaporation at 150 rpm and 60°C for approx. 1 hr, the rotary evaporator 
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was switched off thus, releasing the negative pressure and detaching the 
flask. The resultant powdered formulation (i.e. the granules) was referred 
to as proniosomes that comprised a ratio of 5:1 (w/w) sucrose to lipid 
phase mixture. The proniosomes were collected and hydrated by addition 
of deionised water (approx. 40°C) and shaking to generate niosomes. 
The vesicles were reduced in size using bath sonication and further by 
using a probe sonicator as performed for the conventional niosomes. 
Alternatively, a high shear homogeniser Nano Debee (B.E.E 
International, INC) was used to generate niosomes from proniosomes, as 
explained in section 2.2.14.  
 
 
 
Fig 2.1: A modified rotary evaporator with a feed-line spray system 
for manufacturing proniosomes (Adapted from Song et al., 2002) 
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2.2.5 Size analysis of niosomes 
 
Size analysis of niosome samples was performed by using the Malvern’s 
Zetasizer (Malvern Instruments Ltd., UK) which employed Photon 
Correlation Spectroscopy (PCS) and performed measurements of 
particles in the range between 3 nm and 6 µm. Size analysis was 
conducted by adding niosomes (1 ml) into a Malvern’s disposable vial 
(Malvern Instruments Ltd., UK). The measurements were conducted 
three times and the Zeta average (Zaverage) and polydispersity index (PI) 
were recorded to represent the size and size distribution, respectively.  
 
2.2.6 Zeta potential (surface charge) analysis 
 
Zeta potential of niosomes was measured using Laser Doppler 
velocimetry, again by employing the Zetasizer (Malvern Instruments Ltd., 
UK). A zeta cell was washed several times with deionised water. 
Niosome formulation (700 µl) was added to the zeta cell using an 
automatic pipette. This was done carefully in order to avoid formation of 
air bubbles within the cell. The zeta potential was measured in triplicate 
and the resultant value was presented as the mean (± standard 
deviation).  
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2.2.7 Transmission electron microscopy (TEM) 
 
Transmission electron microscopy (TEM) was performed to investigate 
the morphology of niosomes manufactured using the conventional or 
proniosome methods. This took place by placing a drop of noisome 
suspension onto carbon-coated copper grids (400 mesh pores). The 
sample was negatively stained with (1% Au) uranyl acetate. The resultant 
mixture was left for 2 min to allow its absorption on the carbon film. This 
was followed by viewing the vesicles and taking photographs to 
investigate their morphology using the Philips CM-120 BioTwin 
transmission electron microscope (Philips Electron Optics BV, The 
Netherlands). 
 
2.2.8 UV analysis of BDP 
 
BDP (10 mg) was weighed in a 100 ml volumetric flask and made up to 
the volume with HPLC-grade methanol. The solution was gently mixed to 
allow complete dissolution of BDP. A series of dilutions with methanol in 
volumetric flasks (5 ml each) was performed to obtain drug 
concentrations of 0, 10, 12.5, 20, 25, 30, 40 and 100 µg / ml. The UV-
spectrophotometer was used to measure the absorbance of the samples 
at a UV wavelength of 238 nm (Batavia et al. 2001). This was followed by 
constructing a calibration curve. 
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2.2.9 Drug entrapment studies 
 
BDP was included within the lipid phase (surfactant and cholesterol) to 
be entrapped in the niosomal membranes upon hydration of the thin lipid 
film or proniosomes. This procedure was applied only after probe 
sonication of the niosome dispersions. Thus, after probe sonication, the 
unentrapped fraction of the steroid was separated using 0.45 μm sterile 
cellulose acetate membrane syringe filters (Sigma-Aldrich). To quantify 
the amount of BDP in the vesicles, methanol was used to disrupt the 
niosomes, dissolve the components of the lipid phase and hence convert 
these components into a lipid solution that contains BDP. The amount of 
BDP was quantified using UV spectrophotometer against a blank of lipid 
phase without BDP. The entrapment efficiency (EE) of the steroid was 
calculated as follows:  
EE (%) = (amount of drug entrapped / total drug amount in the 
formulation) X 100%. 
 
Below is the detailed procedure of the EE study: 
1. After homogenisation of the particles (niosomes or proniosomes), 
5 ml was filtered through 0.45 μm filters. 
2. The filtered fraction (entrapped fraction) was diluted with 
methanol. A volume of 1 ml of the entrapped fraction was taken using a 
pipette into 10ml volumetric flask which was then diluted up to volume 
with HPLC grade methanol. This step was repeated again to dilute the 
sample. The diluted sample was measured for UV absorption. 
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3. The UV-reading was placed in the equation of the calibration 
curve and calculated as the amount of the drug in mg. 
 
 
2.2.10 Aerosol droplet size analysis 
 
In this study three nebulisers were investigated: 
1. Pari LC Sprint (Air-jet) nebuliser attached to Pari TurboBoy S 
compressor (Pari GmbH, Germany). 
2. Aeroneb Pro (Vibrating-mesh) nebuliser (Aerogen, Ireland). 
3. Omron MicroAir NEU22 (Vibrating-mesh) nebuliser (Omron 
Healthcare, Japan) and purchased from EverGreen, UK.  
 
 Niosomes generated from proniosomes (2.5 ml) were pipetted into 
the nebuliser which was previously directed with its mouthpiece 
perpendicular to the laser beam of the Malvern’s Spraytec laser 
diffraction instrument (Malvern Instruments Ltd., UK) with a distance of 
approx 3 cm from the beam (Fig. 2.2). The nebuliser was operated to 
commence aerosolisation of the niosomes to “dryness” (i.e. until aerosol 
generation completely ceased). The volume median diameter (VMD, 
50% undersize) of the droplets and the Span value were recorded to 
represent the size and size distribution of the droplets respectively. Span 
= (90% undersize – 10% undersize) / VMD.  
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Fig 2.2: A schematic presentation of a laser diffraction aerosol 
particle size analyser 
 
 
2.2.11 Determination of nebuliser output 
  
As a matter of fact, nebulisers do not deliver all of the medical fluid and 
always a fraction of the fluid originally placed in the nebuliser reservoir 
remains as a “residual volume” (Clay et al., 1983). The amount of fluid 
delivered from nebuliser is referred to as the aerosol output. However, 
most important is the drug output which is the percentage amount of the 
drug successfully delivered as aerosols out of the total amount of drug 
originally placed in the nebuliser. For each nebuliser, niosomes (2.5 ml) 
were placed in the nebuliser and nebulisation was commenced and 
continued to “dryness”. Thus aerosol mass output was determined 
gravimetrically by weighing the nebulisers before and after nebulisation. 
Drug output was determined using UV spectrophotometer to measure the 
quantity of BDP in the residual volume. The amount of BDP delivered 
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was calculated by subtracting the amount of BDP in the residual fluid 
from the total amount of BDP originally placed in the nebuliser.  
 
2.2.12 Estimation of “fine particle fraction”, prediction of alveolar 
deposition and extrathoracic deposition 
Using the Spraytec laser diffraction instrument, the percentage of drug 
delivered in droplets, having a size below 5.4 µm, below 2.1 µm and 
greater than 11.6 µm, was measured to represent the “fine particle 
fraction” of the aerosols, the predicted alveolar deposition and the 
extrathoracic deposition, respectively.  
 
2.2.13 Freeze-drying of niosomes generated from proniosomes 
 
Proniosomes (560 mg) were hydrated according to the procedure 
described in section (2.2.3) using 30 ml of deionised water. Niosomes (4 
ml) were freezed at -20 °C overnight followed by drying using a freeze 
dryer (Alpha 2-4 LD Plus, Christ, Germany) to yield a lyophilized “cake” 
of niosomes. The lyophilisate was rehydrated with deionised water (4 ml) 
with vortex mixing for 4 min. A sample (1 ml) was taken for size analysis 
using photon correlation spectroscopy (section 2.2.5) and zeta potential 
analysis using laser Doppler velocimetry (section 2.2.6). Further 
experiments were conducted to calculate the EE of BDP by filtration of 
the niosome dispersion through microfilters (0.45 µm). The filtered liquid 
(0.5 ml) was taken for UV spectrophotometric analysis to calculate the 
EE as previously described. 
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2.2.14 High shear homogenisation of proniosomes 
 
This experiment was conducted to investigate the possibility of 
generating niosomes on a large scale from proniosomes. This was 
conducted using the Nano Debee homogeniser (Bee International Inc., 
UK). The Nano Debee homogeniser was washed 5 times to avoid cross 
contamination. Proniosomes were prepared in excess amount. The 
samples used in the Nano Debee homogeniser were 60 ml proniosome 
suspension. The proniosome suspension was homogenised via the 
Nano-Debee for 12 circles to reduce the size of the vesicles. Size and 
zeta potential studies were conducted by following the procedures 
previously described. 
 
2.3.1 Statistical analysis 
 
All experiments were prepared three times and the results were 
expressed as the mean ± standard deviation (SD).  One way analysis of 
variance (ANOVA) followed by Tukey Kramer test were performed using 
Graphpad instat® to check the significance between various groups. A 
difference was considered to be significant when the p-value was less 
than or equal 0.05. 
 
 
 
  
 
 
 
 
Chapter 3 
 
 
 
 
Characterisation of conventional 
niosomes and niosomes generated 
from proniosmes and performance of 
nebulisation studies 
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3.1 Introduction 
Previously, proniosomes have been introduced as a stable powder 
alternative to the liquid formulations of niosomes, offering advantages in 
terms of formulation stability and shipping expenses. Characterisation 
studies on the properties of niosomes and proniosomes have been 
performed to investigate whether niosomes generated by using the 
proniosome method would be advantageous to the conventional method. 
The conventional niosomes were prepared by using the thin film 
hydration method and proniosomes were prepared by spraying a 
chloroformic solution of the lipid phase onto the carbohydrate carrier 
particles (e.g. sucrose). Particle size analysis, zeta potential (surface 
charge) measurements, microscopic morphology investigations and drug 
entrapment efficiency studies were conducted. Furthermore, the effect of 
drug loading on particle size, zeta potential and vesicle morphology was 
evaluated. 
 
3.2 Particle size analysis 
Table 3.1 shows the mean particle size of niosomes generated using the 
thin film method and those prepared from proniosomes. Using the thin 
film method or the proniosome technology, three different 
homogenisation techniques were employed to generate niosomes. The 
techniques performed were hand-shaking, bath sonication or probe 
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sonication. It has been found that the size of vesicles generated from 
proniosomes was significantly larger (P<0.05) than that of conventional 
niosomes, regardless of the homogenisation technique.  
 
Amongst the three homogenisation techniques, hand shaking has 
generated niosomes that are markedly larger than the vesicles prepared 
using sonication (Table 3.1). This is attributed to the higher energy input 
by sonication which caused the niosomes to fragment into smaller 
vesicles. Similar findings have been reported for liposomes, and probe 
sonication is well established as a technique that converts large 
multilamellar liposomes (MLVs) into small unilamellar vesicles (SUVs) 
having a size of 100 nm or smaller (Elhissi et al., 2010). The large size of 
niosomes generated from proniosomes might be attributed to possible 
aggregation of the vesicles, especially when no sonication was applied 
(Table 3.1).  
 
Apparently, niosomes prepared by hand shaking were not 
adequately dispersed in the aqueous phase, resulting in aggregation of 
the vesicles. Therefore, manual shaking alone was not enough to 
produce a homogenised suspension of niosomes. In addition, the larger 
size of niosomes produced by hand shaking was accompanied by a 
measured polydispersity index (PI) larger than 0.6, confirming the 
aggregation behaviour. Thus, probe sonication was necessary to 
generate small niosomes in the range of 150-250 nm. It has been 
previously demonstrated that niosome agglomerates are broken up by 
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probe sonication (Jiang and Oberdȍrster, 2009), which agrees with our 
finding that employed BDP proniosomes. 
 
 
 
 
Table 3.1: Size analysis of niosomes produced by conventional 
method and proniosome technology 
 (Data are mean ±SD, n=3,*= P < 0.05) 
 
 
 
 
 
Method 
 
Size of niosomes (nm) 
 Hand shaking Bath sonication Probe sonication 
Thin film 1847.0 ±359.40 684.6 ±2551 156.9 ±8.0 
Proniosome 5312.3±1310.6* 1019.9 ±288.8* 236.5 ±15.3* 
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3.3 Zeta potential analysis 
Table 3.2 shows the zeta potential measurements for niosomes 
generated from proniosome and conventional methods. Regardless of 
the preparation method, the surface charge of niosomes was negative. 
However, the intensity of the negative charge was higher (P<0.05) for 
the proniosome formulations (Table 3.2). It is possible that an 
interaction between sucrose molecules and vesicle membranes has 
occurred, causing a difference in charge distribution on vesicle 
surfaces. Further studies are required to investigate the validity of this 
hypothesis. 
 
 
Table 3.2: Zeta potential analysis of niosomes produced by 
conventional method and proniosome technology  
(Data are mean ±SD, n=3, *= P < 0.05) 
 
 
Method 
 
Zeta potential of niosomes (mV) 
 
 
Hand shaking 
 
Bath sonication 
 
Probe sonication 
 
Thin film 
 
-22.4 ±1.6 
 
-16.8 ±2.4 
 
-22.0 ±2.1 
 
Proniosome 
 
-54.5 ±3.9* 
 
-24.1 ±4.9* 
 
-35.7 ±3.7* 
 
50 
 
 
  
The higher charge intensity on niosomes derived from proniosomes 
possibly indicates higher storage stability of the liquid dispersions of 
these vesicles as compared to the conventional niosomes (Klang et al., 
2010). The presence of similar charge on vesicles may enhance the 
repulsion between them and moreover, can minimize the possible 
aggregation or fusion. It has been previously reported that a decrease in 
electrophoretic mobility of particles may increase the negativity of the 
surface charge of the particle (Junyaprasert et al., 2008). It is likely that 
the larger size of niosomes generated from proniosomes (Table 3.1) has 
slowed the electrophoretic mobility of the vesicles, causing the surface 
charge to be highly negative. A long term stability study is needed in the 
future to investigate the differences in stability between vesicles 
generated using different methods.  
 
 
3.4 Morphology of niosomes 
TEM studies showed that both conventional and proniosome methods 
generated highly spherical noisomes (Fig. 3.1 and Fig. 3.2). Fig. 3.1b 
shows that conventional niosomes were aggregated even after bath 
sonication for 5 min. The size of these vesicles was large (approx. 700 
nm) (Fig. 3.1.b), agreeing with the size analysis findings (Table 3.1) and 
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indicating that the energy input by bath sonication was not sufficient for 
producing mono-dispersed small vesicles. 
 
Hand shaking of proniosomes for 10 min has generated very large 
and highly aggregated niosomes (Fig. 3.2a). However, the size observed 
by TEM (Fig. 3.2) was obviously smaller than that measured using 
photon correlation spectroscopy (Table 3.1). This might be attributed to 
the negative pressure applied while conducting the TEM experiments, 
resulting in damaging the larger vesicles and subsequently only the 
smaller niosomes were viewed. Fig. 3.2 also demonstrates that the 
extent of agglomeration of niosomes generated from proniosomes was 
much higher than that of niosomes produced using the thin film method 
(Fig. 3.1). The inclusion of BDP does not seem to have any effect on the 
morphology and aggregation of niosomes (Fig. 3.2).  For the TEM 
studies, it was necessary to get pictures of the samples at different 
magnifications to get more detailed shape of the particles.    
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53 
 
                                                      
 
  
   
   
  
 
                     (C) 
                                                                                                     
 
 
 
                                                                                                                                                                                                                                                               
                                                                              
                                                                    
 
   (d)                                                                                      
Fig 3.1:  Transmission electron photomicrographs of BDP-loaded 
conventional niosomes using different homogenisation techniques 
a) Handshaking b) Bath sonication at magnification: 24500X c) Bath 
sonication at 65000X d) Probe sonicated particles. (n=3) 
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(c) 
         
 
 
 
 
 
 
 
 
 
 
 
(d) 
 
Fig 3.2: Transmission electron photomicrographs of empty and 
BDP-loaded niosomes derived from proniosomes. The empty 
niosomes are shown using different homogenisation techniques at 
different magnifications a) handshaking b) Bath sonication, whilst 
BDP-loaded niosomes are shown at different magnifications using 
c) bath sonication and d) probe sonication. (n=3) 
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3.5 Size and zeta potential analysis of BDP containing 
niosomes 
Liposomes in the micrometer size range are highly unstable during 
nebulisation. This was demonstrated by the massive losses of the 
entrapped materials (Niven et al., 1991; Elhissi et al., 2007). Moreover, 
large liposomes are highly resistant to atomisation within nebulisers, 
which may result in poor output and prolonged nebulisation time (Elhissi 
et al., 2006). Since niosomes prepared by hand shaking without 
sonication are very large, they are expected to be highly resistant to 
delivery from the nebulisers. Earlier investigations of this project have 
shown that probe sonicated niosomes were the smallest and hence 
nebulisation studies were carried out using niosomes generated by the 
probe sonication technique.  
  
Table 3.3 shows the size and zeta potential of BDP-loaded 
niosomes prepared by the conventional method and those generated 
from proniosomes. Niosomes generated from proniosomes had larger 
size (P<0.05) and more negative surface charge (P<0.05) than vesicles 
prepared using the conventional thin film method (Table 3.3). When the 
size of BDP-included niosomes (Table 3.3) was compared to that of the 
corresponding BDP-free vesicles (Table 3.1), there was only a slight 
trend of increase in vesicle size upon inclusion of the BDP. Also, no 
effect (P>0.05) on the zeta potential was observed upon inclusion of the 
drug.  
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Table 3.3: Size and zeta potential of probe sonicated BDP 
containing niosomes using the conventional and proniosome 
methods 
(Data are mean ±SD, n=3, * = P< 0.05) 
 
 
 
 
 
3.6 Entrapment efficiency (EE) of BDP in niosomes 
Table 3.4 and Fig. 3.3 show a linear relationship between the 
concentration and absorbance of BDP. Using a personal computer, a 
regression line of the data (Table 3.4) was calculated for the different 
concentrations in HPLC-grade methanol at 239 nm. Thus, UV-
spectrophotometer is a suitable technique to quantify BDP. 
 
 
 
 
Method 
 
Size and zeta potential of niosomes 
 
 
Size (nm) 
 
Zeta potential (mV) 
Thin film 
 
160.7 ±4.1 
 
-25.2 ±1.8 
Proniosome 
 
202.5 ±9.5* 
 
-36.2 ±3.3* 
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Table 3.4: Relationship between concentration and absorbance for 
BDP in methanol at a wavelength of 239 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BDP concentration (µg/ml) 
 
Absorbance 
0 0 
10 0.28 
12.5 0.353 
20 0.565 
25 0.723 
30 0.844 
37.5 1.124 
40 1.143 
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Fig 3.3: Calibration curve of BDP in methanol at a wavelength of 239 
nm 
 
Using only the probe sonicated formulations, compared to the 
conventional niosomes, vesicles generated from proniosomes have 
demonstrated higher EE (P<0.05) for the BDP steroid (Fig. 3.4). The 
results revealed that the EE of BDP in proniosome-derived niosomes 
was 36.4% compared to an EE of 27.5% offered by the conventional 
niosomes. This demonstrates that the proniosome method does not only 
provide a means for higher stability but also could be employed to 
enhance the entrapment of this antiasthma steroid.  
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Fig 3.4: Charts showing EE (%) of BDP in conventional niosomes 
manufactured by using the thin film method and in niosomes 
generated from proniosomes 
(Data are mean± SD, n=3, * = P< 0.05) 
 
For liposomes, it has been shown previously that the larger the 
liposomes the greater the EE of beclomethasone (Darwis and Kellaway, 
2001). Thus, the higher EE using the proniosomes might be attributed to 
the larger size of the vesicles. It is also possible that sucrose molecules 
in proniosome formulations have interacted with the niosome 
membranes, preventing the leakage of the drug. To investigate the 
validity of this hypothesis, further studies are needed. Additionally, from a 
technical perspective, the reason of higher drug entrapment in 
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proniosome-derivate niosomes is that coating of lipid onto sucrose 
particles has caused more efficient hydration and subsequent generation 
of vesicles. In contrast for the conventional method, the lipid film was 
highly sticky to the inner flask surfaces, causing difficulty in hydration and 
lower EE of the drug. Abd-Elbary et al (2008) have shown that hydration 
of surfactants was optimal upon the use of the proniosome method. 
 
3.7 Aerosol mass and drug output study 
Nebulisers are capable of delivering large volumes of aerosol from simply 
prepared solutions or dispersions (Terzano et al., 2007), justifying their 
use in this study. The aim of this study was to investigate the nebulisation 
of BDP in niosomal formulations using the proniosome method in terms 
of aerosol mass output and drug output. This study was conducted using 
three nebulisers operating at different mechanisms, namely the Pari LC 
Sprint (air-jet), the Aeroneb Pro (actively vibrating-mesh) and the Omron 
MicroAir (passively vibrating-mesh) nebulisers. The use of the 
proniosome method is justified by the higher EE of the steroid in 
niosomes (Fig. 3.4).  
 
 Aerosol mass and drug output of niosomes were calculated for the 
three different nebulisers used in this study (Fig. 3.5). After nebulisation 
to “dryness” none of the devices delivered 100% of the formulation, 
which is consistent with the previous findings using liposomes (Elhissi et 
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al., 2006; 2007). On completed nebulisation, a “dead” or “residual 
volume” is left within the nebuliser reservoir. The quantity of the “residual” 
volume is dependent on both nebuliser type and formulation 
characteristics (Ghazanfari et al., 2007).   
  
 For the Pari (jet) nebuliser, aerosol output was slightly but 
significantly (P<0.05) higher than drug output (Fig. 3.5). By contrast, the 
Aeroneb Pro (mesh) device demonstrated a trend of higher aerosol 
output than drug output but that was not statistically significant (P>0.05) 
(Fig. 3.5). This higher aerosol output trend indicates a trend for 
accumulation of some BDP within the Pari and Aeroneb Pro nebulisers at 
the end of nebulisation. For the jet nebuliser, this might be attributed to 
solvent evaporation from the aerosols during jet nebulisation, causing the 
drug to concentrate within the nebuliser (O’Callaghand & Barry, 1997).  
For the Aeroneb Pro device, it is possible that some mesh pores were 
blocked by the niosomes or that niosomes were aggregated within 
nebuliser, resulting in a trend of higher mass output than drug output.  
  
 The Omron (mesh) nebuliser behaved differently as the drug 
output was significantly (P<0.05) higher than aerosol output (Fig. 3.5), 
indicating preferential delivery of BDP compared to the other components 
of the niosome formulations. Previous investigations have shown this 
nebuliser to be highly dependent on formulation physicochemical 
properties such as viscosity, surface tension and presence of electrolytes 
within formulation (Ghazanfari et al., 2007).     
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 When the Pari (jet) and the Aeroneb Pro (mesh) were compared, 
the mass output for both devices was similar and so was the drug output, 
with relatively high output values (Fig. 3.5), clearly indicating higher 
delivery performance of niosomes when either of these devices was 
employed. By contrast, the aerosol and drug outputs demonstrated by 
the Omron (mesh) were significantly lower (P<0.05) than outputs from 
the other two nebulisers (Fig. 3.5).  
  
 Although, the Omron (mesh) nebuliser represents the lowest 
outputs, it is important to report that drug output from this device was 
approximately 70% (Fig. 3.5), suggesting that this device is suitable for 
delivery of niosomes generated from proniosomes. Literature findings 
reveal that both air-jet and vibrating-mesh nebulisers are far more 
efficient than ultrasonic nebulisers in delivery of vesicle-based 
dispersions (e.g. liposomes) (Elhissi and Taylor, 2005), which explains 
the reason behind excluding ultrasonic nebulisers from this study.  
  
 Noteworthy, it was observed that the Pari (jet) nebuliser has 
completed nebulisation in approximately 10 minutes whilst the vibrating-
mesh devices required at least 20 minutes. This indicates that the jet 
nebuliser is more efficient and may enhance patient compliance to 
nebulisation therapy when this formulation is used.    
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Fig 3.5: Charts showing aerosol and drug outputs of niosomes 
generated from proniosomes using Omron MicroAir NE U22 
(passively vibrating-mesh), Aeroneb Pro (actively vibrating-mesh) 
and Pari LC Sprint (air-jet) nebulisers 
 (Data are mean ± SD, n=3, * = p< 0.05) 
 
 
3.8 Aerosol droplet size analysis and predicted pulmonary 
deposition 
In this study, size and size distribution of the aerosol droplets generated 
from the nebulisers were measured using laser diffraction and presented 
as the median particle size based on a volumetric particle size 
distribution (Dv50) and Span respectively (Table 3.5). Moreover, the 
fraction of the delivered drug in droplets having a size below 5.4 µm, 
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below 2.1 µm and above 11.6 µm were recorded to represent the “fine 
particle fraction” (FPF), the predicted alveolar deposition and the 
predicted extrathoracic deposition respectively (Fig. 3.6). 
 
The Dv50 of aerosol droplets generated from the Omron (mesh) 
nebuliser were significantly larger (P<0.05) than the droplets generated 
from the Aeroneb Pro (mesh) and the Pari (air-jet) nebulisers (Table 3.5). 
However, no significant (P>0.05) difference was found between the Dv50 
for the jet and aeroneb Pro devices (P>0.05) (Table 3.5).  
 
Similarly, the Span of the aerosol droplets were not different 
(P>0.05) when the Pari (jet) and the Aeroneb Pro (mesh) nebulisers were 
compared (Table 3.5). The Dv50 of aerosols generated from the Omron 
was the highest (P<0.05), indicating larger size of the aerosols (Table 
3.5).  
 
It is possible that the passive vibrations of the Omron’s mesh 
means that liquid is broken up into large droplets whilst the active 
vibrations of the mesh in the Aeroneb Pro device ensures an adequate 
conversion of the nebuliser fluid into smaller droplets that are equivalent 
in size to the droplets generated from the Pari (jet) nebuliser. 
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Table 3.5: Median size (Dv50) and Span of aerosol droplets 
generated from niosomes using different types of nebulisers  
(Data are mean ± SD, n=3, * = P< 0.05) 
 
 
 
Nebuliser 
 
 
Dv50 (µm) Span 
Omron NEU22 (mesh) 4.86 ± 0.16* 1.35 ± 0.33 
Aeroneb Pro (mesh) 3.32 ± 0.17 1.52 ± 0.09 
Pari LC Sprint (jet) 3.06 ± 0.15 1.33 ± 0.12 
 
 
It has been previously reported that the suspended particles within 
nebuliser should be smaller than 2 µm in order to be easily incorporated 
in droplets having a diameter of 3 µm (Dahlback, 1994).  Thus the size of 
droplets in this study indicates the suitability of the three nebulisers for 
delivery of niosomes generated from proniosomes, since the vesicles 
had much smaller size (Table 3.3) that would permit them to be 
incorporated into the generated aerosol droplets. In addition, the devices 
investigated in this work demonstrated that the generated aerosols are 
likely to deposit in high FPF. 
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There are many factors that influence deposition of particles in the 
respiratory tract. However, principally for particles to be considered 
therapeutically useful or in “FPF” (i.e. suitable for deposition in 
bronchioles and alveolar region) they should have a size below 5 - 6 µm, 
with particles below 2 µm being more likely to deposit in the alveolar 
region (O’Callaghan and Barry, 1997; Terzano et al., 2007). Particles that 
are larger than 12 µm may deposit in the extrathoracic region (Heyder, 
1982), indicating their unsuitability for pulmonary delivery. Fig. 3.6. 
demonstrates the predicted regional distribution of the aerosol droplets in 
the respiratory system based on laser diffraction analysis. Droplets of 
size less than 5.4 µm, less than 2.1 µm and greater than 11.6 µm were 
recorded to represent the FPF, predicted deposition in the alveolar region 
and predicted deposition in the extra-thoracic region, respectively. 
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Fig 3.6: Charts showing predicted regional deposition of the 
nebulised BDP using the three nebulisers 
 (Data are mean ± SD, n=3* = P < 0.05) 
 
  
Similar to Dv50 and Span findings, the Aeroneb Pro (mesh) and Pari (jet) 
nebulisers were similar in generating droplets with high FPF and 
predicted alveolar deposition, whilst the Omron device generated 
droplets with much lower FPF (P<0.05) and negligible alveolar deposition 
(Fig. 3.6). This again demonstrates that the Pari and the Aeroneb Pro 
nebulisers operate by mechanisms that are more appropriate for delivery 
of niosomes to the deep lung. The predicted extrathoracic deposition was 
negligible for all devices (Fig. 3.6). Noteworthy, although the Omron 
seemed to be the least appropriate for delivery of niosomes, it generated 
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droplets with 42% FPF (Fig. 3.6), indicating its suitability for delivering 
BDP-niosomes.  
 
 Thus, the proniosome technology represents a successful 
approach to delivering BDP in niosomes with high FPF when air-jet or 
vibrating-mesh nebulisers are used.  
 
3.9 Freeze-drying of niosomes generated from proniosomes 
Freeze-drying is a widely used technology in pharmaceutical industry to 
stabilise therapeutic agents or enhance their solubility or dispersion in 
aqueous environments. Freeze-drying has been used to stabilise 
liposomes (van Bommel and Crommelin, 1984). Delivery of freeze-dried 
liposomes via jet nebulisers has been shown to be achievable using 
beclomethasone as a model antiasthma steroid (Darwis and Kellaway, 
2001). However, to avoid aggregation and fusion of freeze-dried 
liposomes upon rehydration, cryoprotectants (e.g. carbohydrates) are 
commonly added prior to freeze-drying (van Bommel and Crommelin, 
1984). 
 
 In this study, niosomes generated from proniosomes were freeze-
dried and rehydrated in order to investigate the possibility of 
manufacturing freeze-dried niosomes. No cryoprotectant was added 
since sucrose was one of the proniosome components.  
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 Unfortunately, rehydration of niosomes caused a massive 
increase (by more than 13 times) in the measured particle size (Table 
3.6). Freeze-drying of cryoprotected small unilamellar BDP-liposomes did 
not massively increase the size upon rehydration (Elhissi et al., 2011), 
contrary to our observation for niosomes which demonstrated an 
increase from the nanometer range to higher than 3 µm (Table 3.6). This 
suggests different behaviour of niosome membranes compared to 
liposome membranes. Further investigations are needed to provide a 
better understanding of the aggregation behaviour of niosomes upon 
freeze-drying and rehydration.    
 
 
 
Table 3.6: Size, zeta potential and drug EE using niosomes 
generated from pronisomes before freeze-drying and upon 
rehydration of freeze-dried formulation 
 (Data are mean ± SD, n=3,* = P < 0.05 
  
 
Formulation Size (nm) 
Zeta potential  
(mV) 
EE (%) 
Niosomes 236.5 ±15.3 -35.7 ±3.7 36.4 ±2.81 
Freeze-dried niosomes 3125.3 ±667.4* -28.27 ±7.47 24.85 ±10.66* 
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Zeta potential had a trend to become less negative as a result of 
freeze-drying and rehydration, however, the change in zeta potential was 
not statistically significant (Table 3.6). This trend for change in the 
surface charge might be attributed to the massive increment in the 
measured size of vesicle (Table 3.6). If no cryoprotectant (e.g. sucrose) 
was included, small liposomes tend to considerably aggregate or fuse 
(Elhissi et al., 2010). However, for niosomes generated from 
proniosomes, although the cryoprotectant (i.e. sucrose) was included 
prior to freeze-drying the measured size increased dramatically, 
suggesting niosomes may require different cryoprotection mechanism. 
  
 Compared to unfreeze dried niosomes, the EE of BDP tended to 
decrease upon freeze-drying and rehydration, however, the entrapment 
values were inconsistent, with no statistically significant change being 
observed (P>0.05),  possibly reflecting instability of the niosome 
formulation (Table 3.6). The trend for decreased EE of BDP might be 
attributed to drug leakage from niosomes as a result of vesicle 
aggregation or fusion. BDP is a hydrophobic drug and its association with 
the niosome membranes may have minimised its loss upon aggregation 
or fusion of vesicles. By contrast, previous findings using hydrophilic 
drugs have shown that leakage is significant upon aggregation or fusion 
of freeze-dried liposomes (Van Winden, 2003). It is suggested that the 
increased size of niosomes may make nebulisation less efficient or even 
unsuitable. Further work is needed to investigate this.   
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3.10 Niosmes generated from proniosomes using high shear 
homogenisation 
This study aimed to introduce a method that might be employed for large 
scale manufacturing of niosomes. Proniosomes were manufactured and 
hydrated by hand shaking to generate niosomes. This was followed by 
size reduction in a Nano Debee homogeniser. This approach has shown 
to be successful since niosomes had a small size after homogenisation 
which is similar to that using the probe sonication technique (Table 3.7). 
Probe sonication may heat formulation and probes made of titanium may 
cause contamination of the preparation, resulting in limited use of this 
technique. In addition, heating might damage thermolabile drugs and 
thus, enhance the rate of oxidation for liable materials. By contrast, 
homogenisation using the Nano Debee homogeniser provides the 
advantage of safety, absence of titanium contamination and similar 
efficiency in vesicle size reduction without heating the preparation.   
 
Table 3.7 revealed no significant difference (P>0.05) in particles 
size and surface charge (zeta-potential) between the two different 
methods of homogenisation namely the probe sonication and the Nano 
Debee homogenisation. The only difference was that the PdI of the 
particle size using Nano Debee homogeniser was around 0.5 whilst as 
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low as 0.3 or less by using the probe sonication, which indicates that 
probe sonication is more capable of reducing the vesicle polydispersity.  
 
From a practical perspective, this might not negatively affect the 
applicability of the Nano Debee homogenisation method. Nano Debee 
offered the possibility of homogenisation much larger volumes of 
niosomes compared to probe sonication.  
 
 
 
Table 3.7: Size, zeta potential and drug EE for niosomes generated 
from pronisomes using probe sonication or Nano Debee 
homogenisation 
 (Data are mean ± SD, n=3) 
 
 
 
Production method 
 
Size (nm) 
 
Zeta potential 
(mV) 
 
EE (%) 
 
Probe sonication 
 
 
236.5 ±15.3 
 
-35.7 ±3.7 
 
36.4 ±2.81 
 
Nano Debee 
homogenisation 
 
209.17 ±21.4 
 
-38.0 ±6.42 
 
29.65 ±4.04 
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It has been observed that the EE of BDP in niosomes 
homogenised by the Nano Debee homogeniser was not significantly 
different (P>0.05) from that offered by probe sonication (Table 3.7), again 
confirming that the use of Nano Debee homogeniser to homogenise 
niosomes in a relatively large scale was successful with only minimal 
compromisation of the quality of formulation. Further studies are required 
to investigate the behaviour of Nano Debee homogenised vesicles during 
nebulisation and the regional deposition of BDP in the respiratory tract.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter 4 
 
 
 
 
Conclusions and future work 
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4.1 Introduction 
This chapter summarises the findings of this research and draws a map 
for the future investigations by our research group. The main idea behind 
using niosomes instead of liposomes was to avoid the instability 
problems of liposomes. Phospholipids in liposomes as are liable to 
hydrolysis or oxidation and liposomes as liquid dispersions may 
aggregate or fuse during storage with a subsequent leakage of the 
entrapped material. Initially proliposomes have been postulated as a 
potential resolution for the instability manifestations of liposomes. One 
type of proliposomes is the particulate-based type which represents 
carbohydrate carrier particles coated with phospholipids, followed by 
storage at low temperature (e.g. -20°C). Once liposomes are needed, an 
aqueous phase is added to the proliposomes with shaking to generate 
liposomes. The storage of proliposomes at this very low temperature 
aims to protect the phospholipids from hydrolysis and oxidation. In 
developed countries this may not be a difficult requirement, however, 
developing countries which have problems with electricity supply may 
find it very inconvenient to store proliposomes at -20°C. For this reason, 
particulate-based proniosomes have been suggested as an alternative to 
liposomes and proliposomes in our study. 
 
 Proniosomes are carbohydrate carrier particles coated with surfactants 
and cholesterol to generate niosomes upon addition of aqueous phase. 
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Since carbohydrates and surfactants are possible to store at room 
temperature, the storage requirement will not represent a problem for 
developing countries.  
 
4.2 Experimental design  
This study attempted to develop novel proniosome formulations 
containing the antiasthma steroid beclomethasone dipropionate (BDP). It 
was known previously that niosomes could be derived from the 
proniosome formulations. In addition, the properties of niosomes 
manufactured by the conventional thin film method (i.e. conventional 
niosomes) were compared to niosomes generated from proniosomes in 
terms of particle size, zeta potential (surface charge), morphology, 
aggregation behaviour and entrapment efficiency (EE) of BDP. 
 
 Moreover, niosomes generated from proniosomes were 
homogenised (i.e. reduced in size) by different techniques including hand 
shaking alone, hand shaking followed by bath sonication or hand shaking 
followed by bath sonication and probe sonication. The resultant vesicles 
were studies in terms of size, zeta potential and EE of BDP.  
 
 Probe sonicated niosomes generated from proniosomes were 
nebulised using three types of nebulisers: Pari LC Sprint (air-jet), 
Aeroneb Pro (actively vibrating-mesh) and Omron MicroAir NEU22 
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(passively vibrating-mesh) nebulisers. The performance of nebulisation 
using each nebuliser was evaluated in terms of aerosol mass output, 
drug output, median droplet size (Dv50) and droplet size distribution 
(Span). Span = (90% undersize – 10% undersize)/ Dv50. Span here 
does not refer to the well-known group of non-ionic surfactants. It is 
rather a term introduced by Malvern Instruments Ltd., UK (the supplier of 
the instrument used in this study) to express the polydispersity of 
particles. 
 
 In another experiment, the potential of manufacturing niosomes on 
a large scale was explored. High pressure homogenisation using the 
Nano Debee homogeniser was employed to process niosomes that were 
freshly prepared from proniosomes. The resultant vesicles were 
compared to probe sonicated vesicles in terms of particle size, zeta 
potential and EE of BDP.    
    
 Finally, the possibility of manufacturing freeze-dried niosomes 
generated from proniosomes by probe sonication was investigated. The 
particle size, zeta potential and EE of BDP were compared between 
vesicles before freeze-drying and after freeze-drying and rehydration. In 
these experiments, the cryoprotectant used was the sugar originally 
included within proniosomes (i.e. no external cryoprotectant was used).  
79 
 
4.3 General conclusions 
4.3.1 Comparison between conventional niosomes and niosomes 
generated from proniosomes 
 
Using either hand shaking, hand shaking and bath sonication or hand 
shaking with bath and probe sonication, niosomes generated from 
proniosomes were larger than conventional niosomes and had a wider 
size distribution. Morphology studies using transmission electron 
microscopy (TEM) confirmed that niosomes generated from proniosomes 
were aggregated. There was no observed effect of BDP inclusion on the 
aggregation of the niosomes generated from proniosomes.  
 
Moreover, proniosome-generated niosomes had a more intense 
negative zeta potential when compared to the conventional vesicles. This 
was attributed either to the larger size of niosomes or to the presence of 
sucrose in niosomes generated from proniosomes. Taking the probe 
sonicated vesicles as an example, the zeta potential measurements were 
approximately - 25 mV and - 36 mV for the conventional vesicles and 
niosomes generated from proniosomes, respectively. 
 
The EE of BDP was higher in proniosome-derived niosomes than 
in conventional niosomes being around 35% and 27%, respectively 
suggesting the superiority of niosomes manufactured by the proniosome 
technology. 
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Amongst the homogenisation techniques investigated, and using 
thin film method or proniosome technology, probe sonication was found 
to be the most efficient technique in reducing the size and polydispersity 
of niosomes. Thus, using probe sonication, the measured size (Zaverage) 
was 160 nm and 202 nm for conventional niosomes and niosomes 
generated from proniosomes respectively. 
 
4.3.2 Nebulisation output studies 
 
Using the probe sonicated vesicles generated from proniosomes, the 
Pari (jet) and Aeroneb Pro (mesh) nebulisers generated aerosols with 
higher mass output than drug output, contrary to what was found when 
the Omron (mesh) was used.  
 
The output from the Pari and the Aeroneb Pro devices were 
similar (approximately 80% for the drug output and 85% for the mass 
output) and higher than the values found with the Omron nebuliser (drug 
output was around 70%). Overall, all nebulisers were suitable for 
generating niosome aerosols with high aerosol and drug outputs.  
 
4.3.3 Aerosol droplet size analysis and predicted pulmonary 
deposition 
 
This study was conducted using laser diffraction. The Dv50 of droplets 
generated from the Pari and Aeroneb Pro nebulisers were around 3µm 
compared to a Dv50 value of around 5µm generated by the Omron 
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nebuliser. However, the size distribution (Span) presented by the 
Aeroneb Pro device was slightly higher than that for the Omron or the 
Pari nebulisers. 
 
 The study was conducted in order to predict the pulmonary 
deposition of BDP in niosomal formulations. The results have revealed 
higher “fine particle fraction” of the droplets generated from the Pari or 
the Aeroneb Pro nebulisers, being 70% or higher compared to FPF 
values of around 40% for the Omron nebuliser.  
 
 Moreover, the predicted alveolar deposition for the Pari or 
Aeroneb Pro was around 20% compared to 1 or 2% using the Omron 
device. This may suggest that the Omron is unsuitable for targeting the 
alveolar region. All nebulisers generated aerosols with negligible 
predicted extrathoracic deposition.    
  
 Overall, the findings of this study suggest that, if the niosomes are 
to target the bronchioles all nebulisers are potentially suitable, whilst the 
Omron may not be recommended for targeting the alveolar region. 
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4.3.4 Homogenisation using high pressure homogeniser 
 
 
Using the proniosome technology, vesicle size reduction using the Nano 
Debee homogeniser has provided a successful means of producing small 
niosomes (Zaverage = 236.5 ±13 nm) which was comparable to niosomes 
processed via the probe sonicator (Zaverage= 209.2 ±21.4 nm) with no 
statistical difference being detected (P>0.05). 
 
 Moreover, no significant difference (P>0.05) was found in the zeta 
potential of probe sonicated vesicles and niosomes homogenised by the 
Nano Debee homogeniser, being approximately -36 mV and -38 mV, 
respectively. 
 Similarly, the EE of BDP was not statistically different (P>0.05) 
between the two formulations, being 36.4% ±2.8 and 29.65% ±4.04 for 
the probe sonicated vesicles and the Nano Debee homogenised 
vesicles, respectively.  
 
 From a health and safety viewpoint, the Nano Debee homogeniser 
seems better since probe sonication might leach titanium in the niosome 
dispersions. Incomplete removal of that by centrifugation may cause 
undesirable effects in vivo. In addition, with the homogeniser, larger 
volumes can be processed. Overall, these findings indicate that 
homogenisation using the Nano Debee homogeniser is more desirable 
than the traditional method of probe sonication. 
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4.3.5 Freeze-drying of niosomes  
 
In order to optimise an approach that is suitable for large scale 
production of niosomes that are appropriate for nebulisation, probe 
sonicated niosomes were freeze-dried. 
 
 Unfortunately, freeze-drying followed by rehydration has caused a 
marked increase (by more than 13 times) in the measured particle size 
and a trend for inconsistent reduction in the EE of BDP (EE = 24.85% 
±10.66) when compared to vesicles that were probe sonicated without 
freeze-drying (EE= 36.4% ±2.81). However, the zeta potential was similar 
for both formulations.  
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4.4 Scope for future studies 
Due to time limitations many studies have not been conducted. For 
instance, it would have been useful to study the interaction between 
sucrose and the niosome membranes using calorimetric techniques such 
as high sensitivity differential scanning calorimetry. This might possibly 
explain the reasons behind the aggregation behaviour of niosomes 
generated from proniosomes. 
 
 In addition, optimisation of the freeze-drying conditions is required 
in order to produce niosomes that are stable as a freeze-dried 
formulation. This would include future investigations of using 
cryoprotectants other than sucrose or sucrose in different concentrations.  
 
 It would be very interesting to study the in vivo behaviour of 
niosomes generated from proniosomes and compare the findings to 
those of the well established liposome formulations.  
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